statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	477
SG - Singapore	228
RU - Federazione Russa	173
IT - Italia	117
VN - Vietnam	100
CN - Cina	84
BR - Brasile	51
NL - Olanda	45
DE - Germania	32
HK - Hong Kong	25
FI - Finlandia	24
CA - Canada	15
FR - Francia	15
CI - Costa d'Avorio	12
IE - Irlanda	12
UA - Ucraina	11
BD - Bangladesh	10
GB - Regno Unito	7
IN - India	5
JP - Giappone	5
MX - Messico	5
ES - Italia	4
IQ - Iraq	4
TH - Thailandia	4
AR - Argentina	3
AT - Austria	3
ID - Indonesia	3
KR - Corea	3
PK - Pakistan	3
SE - Svezia	3
CO - Colombia	2
EC - Ecuador	2
KZ - Kazakistan	2
MA - Marocco	2
VE - Venezuela	2
BE - Belgio	1
BG - Bulgaria	1
BY - Bielorussia	1
CL - Cile	1
ET - Etiopia	1
GP - Guadalupe	1
GR - Grecia	1
HT - Haiti	1
JM - Giamaica	1
LB - Libano	1
LT - Lituania	1
MD - Moldavia	1
MK - Macedonia	1
MY - Malesia	1
NA - Namibia	1
NO - Norvegia	1
PH - Filippine	1
PL - Polonia	1
PY - Paraguay	1
RO - Romania	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
SN - Senegal	1
TN - Tunisia	1
TR - Turchia	1
UZ - Uzbekistan	1
ZA - Sudafrica	1
Totale	1.520

Nome	#
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR	163
A complicated association between two different genetic rare disorders: Cystic Fibrosis and Spinal Muscular Atrophy	161
Burkholderia cepacia complex infection in a cohort of Italian patients with cystic fibrosis.	141
Long-term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1.	139
Positive expiratory pressure treatment: efficacy in pulmonary diseases	132
Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis	132
Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease	123
Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis.	108
Aspergillosi broncopolmonare	106
Positive expiratory pressure treatment: efficacy in pulmonary diseases.	102
Burkholderia cepacia complex infection in a cohort of Italian patients with cystic fibrosis.	101
Home physiotherapists assisting follow-up treatment in cystic fibrosis: a multicenter observational study	97
Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in a Cystic Fibrosis Child With L1077P Mutation	31
Totale	1.536

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	74	0	0	3	0	0	5	4	3	11	2	23	23
2022/2023	131	11	9	2	9	19	9	2	9	27	26	8	0
2023/2024	120	3	14	17	11	8	13	7	18	1	5	15	8
2024/2025	411	16	25	3	11	17	33	26	36	33	25	153	33
2025/2026	680	69	38	84	59	138	23	60	48	88	47	11	15
2026/2027	4	4	0	0	0	0	0	0	0	0	0	0	0
Totale													1.536